Immunotherapy has become standard of care for all stages of NSCLC. However, there is a gap in knowledge on how to select patients for neoadjuvant immunotherapy followed by surgical resection. In addition, neoadjuvant immunotherapy may pose new challenges in technique aspect of surgical resection. For patients who received adjuvant immunotherapy following concurrent chemoradiation therapy, or stage IV patients who received first line chemoimmunotherapy, many patients develop required resistance to therapy. This section intends to discuss these challenges in practice and future direction.

It is imperative that the clinicians treating lung cancer patients understand the new trend and challenges in immunotherapy and direction of future in this area. This educational session will provide attendees the opportunity to gain exposure to the latest information in combination of immunotherapy in NSCLC and challenges in clinical practice.